Rosiglitazone induces cardiotoxicity by accelerated apoptosis

Area of Science:

• Cardiology
• Toxicology
• Molecular Biology

Background:

• Rosiglitazone (ROSI) is a medication used to treat type 2 diabetes.
• Concerns exist regarding its potential cardiovascular side effects.
• Understanding the mechanisms of ROSI-induced cardiotoxicity is crucial for patient safety.

Purpose of the Study:

• To investigate the cardiotoxicity of rosiglitazone (ROSI).
• To elucidate the underlying mechanisms of ROSI-induced cardiac damage in vitro and in vivo.
• To assess the role of oxidative stress and apoptosis in ROSI cardiotoxicity.

Main Methods:

• Utilized rat heart H9c2 cells and db/db mice models.
• Assessed apoptosis, superoxide generation, and antioxidant enzyme expression (SOD, catalase, GR, GST, GPx).
• Analyzed NADPH oxidase, nitric oxide synthases, heme oxygenase-1, NF-E2-related factor, and protein kinase C δ expression.
• Measured serum creatinine kinase-MB and cardiac troponin T in vivo.
• Performed global gene expression studies.

Main Results:

• ROSI induced apoptosis and superoxide generation in H9c2 cells, linked to increased NADPH oxidase and nitric oxide synthases.
• Antioxidant enzyme expression and heme oxygenase-1 increased, indicating oxidative stress response.
• In db/db mice, ROSI elevated cardiac damage markers (creatinine kinase-MB, troponin T) and antioxidant levels.
• Gene expression studies revealed disruptions in oxidative phosphorylation and electron transport chain.
• ROSI treatment led to accelerated apoptosis in both in vitro and in vivo models.

Conclusions:

• Rosiglitazone (ROSI) induces cardiotoxicity through accelerated apoptosis.
• Oxidative stress plays a significant role in ROSI-induced cardiac damage.
• Findings highlight the importance of monitoring cardiovascular health in patients taking ROSI.